Marketed in 57 countries across Europe, the Americas, and the Asia-Pacific region, Cozaar is a globally distributed brand of losartan, an agent acting on the renin-angiotensin system and classified among the antihypertensive medications that work by blocking AT1-receptors. For an international reader, this is a brand that is frequently encountered abroad — sometimes under the Cozaar name, sometimes as a losartan-containing generic.
Losartan is prescribed in the management of hypertension and a number of related cardiovascular and metabolic conditions, including diabetic kidney disease, heart failure, and cardiovascular risk reduction in selected patient groups. The structured indication list further down this page details the registered uses recognised across the markets where Cozaar is sold, and reflects the fact that this molecule has a broad clinical footprint beyond blood-pressure control alone.
Because Cozaar is so widely distributed, travellers and expatriates routinely come across the same active ingredient under different commercial labels. Markets where Cozaar is registered include Brazil, Australia, China, Canada, and Denmark, but regulatory packaging, prescription pathways, and the mix of branded and generic losartan products differ considerably from one country to another. A pharmacist in the destination country can confirm whether a locally available losartan product corresponds to what the patient was using at home.
Other medications within the angiotensin II receptor blocker class are sold in many of the same markets under different molecules and brand names. Substitution between class members is not a self-service decision: each molecule has its own profile, and a healthcare provider familiar with the patient's full history is the appropriate person to lead any change in long-term cardiovascular therapy.
